Medicus Pharma wins UAE IND nod for genomics-guided endometriosis trial
Medicus Pharma (NASDAQ: MDCX) has received investigational new drug authorisation from the UAE Department of Health in Abu Dhabi to initiate its PRECISION-E2 Phase 2a clinical study, evaluating the GnRH antagonist Teverelix in women with moderate-to-severe symptomatic endometriosis. The authorisation, granted following a full scientific and regulatory review of the company's chemistry, manufacturing and controls, non-clinical and safety documentation, clears the path to site-level IRB and ethics approvals before enrolment can begin.
Endometriosis is a chronic, oestrogen-dependent inflammatory condition estimated to affect roughly one in ten women of reproductive age worldwide. Despite a growing catalogue of approved therapies, including oral GnRH antagonists such as elagolix and relugolix, a substantial proportion of patients continue to experience inadequate symptom control, treatment-related hypoestrogenic side effects, or disease recurrence after stopping treatment.
Study design
PRECISION-E2 is designed as a prospective, randomised, placebo-controlled study enrolling approximately 84 participants across multiple UAE sites. Participants will be allocated equally across four arms: Teverelix 60 mg subcutaneously, Teverelix 90 mg subcutaneously, Teverelix 90 mg intramuscularly, and placebo. The primary pharmacodynamic endpoint is the proportion of women achieving sustained serum oestradiol within the Barbieri therapeutic window of roughly 20 to 50 pg/mL for at least 14 consecutive days after dosing.
What distinguishes the study from conventional Phase 2 endometriosis programmes is its prospective integration of whole-genome sequencing with hormonal pharmacodynamics, pharmacokinetics, bone turnover biomarkers and patient-reported quality-of-life outcomes. Exploratory genomic analyses will focus on predefined genes linked to oestrogen receptor signalling, gonadotropin signalling and pain perception, including ESR1, ESR2, CYP19A1 and GNRHR. Medicus is clear that any biomarker or treatment-response signature identified would require validation in subsequent studies before being used for patient selection.
"PRECISION-E2 has the potential not only to optimise the future development of Teverelix but also is an important step toward personalized therapy that could help redefine how women with endometriosis and other oestrogen-driven diseases are stratified," said Dr Raza Bokhari, executive chairman and chief executive of Medicus Pharma.
Market and competitive context
The GnRH antagonist class in women's health has gained considerable commercial traction since the approval of oral daily formulations. Teverelix is positioned as a long-acting injectable depot intended to offer less-frequent dosing than daily oral alternatives, and without the initial hormonal flare seen with older GnRH agonists such as leuprorelin. If the pharmacodynamic profile holds in clinical data, that could be a meaningful differentiator for patients and prescribers managing adherence. However, the company is at an early stage: PRECISION-E2 is a Phase 2a study focused primarily on pharmacodynamics and safety, and no efficacy readout should be expected from this programme alone.
The genomics-guided approach places Medicus in a small but growing group of developers seeking to move women's health trials beyond binary efficacy endpoints toward biomarker-enriched patient selection. Whether the UAE-based study can attract an enrolment population sufficiently representative to power later regulatory submissions elsewhere will be a key question for investors and potential partners to monitor. Medicus has stated its broader strategy is to generate decision-grade datasets suited to regional licensing or co-development deals with larger pharmaceutical partners, rather than to pursue full commercialisation independently.
The company's other pipeline assets include SkinJect, an immuno-oncology product for basal cell carcinoma, and additional Teverelix programmes in cardiovascular high-risk prostate cancer and benign prostatic hyperplasia-related urinary retention.